Florent Ferré’s Post

The first quarter of 2024 has been active on the M&A side for the Biotech sector with 13 deals (vs. a quarterly average of ~8 deals since 2018). Compared to January, IPO activity for the end of Q1 was quiet.

Soon to IPO

Insightful article on how CFGI supported Upstream Bio's $293 million IPO – a testament to strategic financial guidance and execution excellence - shout if you need help with your IPO readiness! https://lnkd.in/erQrz4Ec

IPO & M&A Roundup for Biotech's - Q1 2024 💸 Exciting developments in the biotech world! Fierce Biotech's quarterly IPO and M&A roundup for Q1 2024 highlights the industry's continued growth and innovation. From groundbreaking mergers to IPO milestones, these trends underscore the dynamism of biotech. Stay updated on the latest advancements. Read more here: https://lnkd.in/eg-uifBT #Biotech #Innovation #IPO #MergersAndAcquisitions

Emcure Pharma gets Sebi approval for IPO: What we know Full Article Link >>> https://lnkd.in/gd94mS4D Welcome To Latest IND >> Fastest World News Jun 20, 2024 02:23 PM IST The IPO includes fresh equity sale worth ₹800 crore and an OFS of 1.36 crore equity shares by promoters and existing shareholders. Emcure Pharma has received Sebi’s nod for the IPO. The company is likely to launch the issue in the […] . . Latest IND . . . . #trendingnews #newstrending #trendingtopicnews #lifestyle #business #news #healthylifestyle #smallbusiness #supportsmallbusiness #lifestyleblogger #luxurylifestyle #businessowner #businesswoman #smallbusinessowner #businessnews

#News: Avid Bioservices a #CDMO specializing in #biologicdrugs, is going private in an M&A deal that values the company at $1.1 billion. The buyers are two private equity firms, GHO Capital Partners and Ampersand Capital Partners. According to terms of the definitive merger agreement announced after Wednesday’s market close, those firms will pay $12.50 in cash for each Avid share, which is a 13.8% premium to Avid’s closing stock price on Wednesday. That price also represents a 21.9% premium to Avid’s average stock price for the 20 days prior to the announcement of the deal. https://lnkd.in/eczzvsk5

Thoughts on this? >> Why Lenz picked a reverse merger instead of an IPO: Q&A >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #biotech #healthcare

According to Bloomberg data, there were only 18 initial public offerings in the biopharma space during 2023, the lowest year for IPOs in the past decade; however, beginning in the fourth quarter of 2023, many in the biopharma sector expressed optimism around potential momentum for initial public offerings.

Sai Life Sciences IPO opens subsequent week. GMP, worth band, date, valuation, different particulars of upcoming IPO in 10 factors - https://lnkd.in/gxsSV2pc

What doesn't work must to be replaced with what works. "Concluding Thoughts: We found little evidence the Inflation Reduction Act has resulted in a meaningful decrease in the level of VC investment in new drug development. Other data reinforce this perspective: Late-stage private company and public equity valuations, IPOs, follow-on offerings, and mergers and acquisitions in biopharma largely held steady in the 18 months since passage of the IRA and have had a positive start in 2024. " -https://lnkd.in/eDh29DDi #pharma #IRA #InflationReductionAct #vcfunding #IPO #funding